CBD - CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare | Benzinga
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporation as the sole agent and sole book-runner on a "best efforts" agency basis in connection with a marketed private placement offering of units of the company at $0.30 per unit for aggregate gross proceeds of up to $3 million.
The Details
Each unit shall comprise one common share of the company and one purchase warrant of the company, with each warrant entitling the holder thereof to purchase one common share at an exercise price of $0.36 for a period of 36 months from closing.
The company will grant the agent ...